A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome

Seong Hyun Jeong, Yoo Jin Kim, Je Hwan Lee, Yeo Kyeoung Kim, Soo Jeong Kim, Sung Kyu Park, Young Rok Do, Inho Kim, Yeung Chul Mun, Hoon Gu Kim, Won Sik Lee, Hyeon Gyu Yi, Young Don Joo, Chul Won Choi, Suk Ran Kim, Sang Min Na, Jun Ho Jang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This prospective observational study evaluated the efficacy and safety of long-term decitabine treatment in patients with myelodysplastic syndrome (MDS). Decitabine 20 mg/m2/day was administered intravenously for 5 consecutive days every 4 weeks to MDS patients in intermediate-1 or higher International Prognostic Scoring System (IPSS) risk categories. Active antimicrobial prophylaxis was given to prevent infectious complications. Overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and time to response were evaluated, as were adverse events. The final analysis included 132 patients. IPSS risk was intermediate-2/high in 34.9% patients. The patients received a median of 5 cycles, with responders receiving a median of 8 cycles (range, 2-30). ORR was 62.9% (complete response [CR], 36; partial response [PR], 3; marrow complete response [mCR], 19; and hematologic improvement, 25). Among responders, 39% showed first response at cycle 3 or later. OS at 2 years was 60.9%, with 17% progressing to acute myeloid leukemia. PFS at 2 years was 51.0%. Patients achieving mCR showed comparable survival outcomes to those with CR/PR. With active antibiotic prophylaxis, febrile neutropenia events occurred in 61 of 1,033 (6%) cycles. Long-term decitabine treatment with antibiotic prophylaxis showed favorable outcomes in MDS patients, and mCR predicted favorable survival outcomes.

Original languageEnglish
Pages (from-to)44985-44994
Number of pages10
JournalOncotarget
Volume6
Issue number42
DOIs
Publication statusPublished - 2015

Keywords

  • Decitabine
  • Long-term treatment
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome'. Together they form a unique fingerprint.

  • Cite this

    Jeong, S. H., Kim, Y. J., Lee, J. H., Kim, Y. K., Kim, S. J., Park, S. K., Do, Y. R., Kim, I., Mun, Y. C., Kim, H. G., Lee, W. S., Yi, H. G., Joo, Y. D., Choi, C. W., Kim, S. R., Na, S. M., & Jang, J. H. (2015). A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome. Oncotarget, 6(42), 44985-44994. https://doi.org/10.18632/oncotarget.6242